PDCD1 and non-small cell lung carcinoma: Background With the shift toward perioperative programmed cell death protein-1 and programmed cell death ligand-1 (PD-L1) immunotherapy in non-small cell lung cancer (NSCLC), there is a need to assess PD-L1 status preoperatively.